FREQUENCY EXCHANGE CORP

DO WELL, AND DO GOOD.

We acquire, develop and enhance bioenergetic-based wearable technologies designed and proven to enhance wellness and performance.

Our subsidiary FREmedica Technologies creates wearable technology that makes life-enhancing frequency programs easily accessible and affordable.



"Future Medicine will be the Medicine of Frequencies." - Albert Einstein

FREmedica owns two preemptive frequency technologies; WAVE 1 and NIKKI.

WAVE 1 offers wearable technology specifically engineered and proven to speed recovery from Lyme disease. WAVE 1 continues to provide relief from Lyme for a growing and global group of customers affected by this disease of epidemic proportions.

NIKKI (launching 2023) is a wearable designed to help with a wide and growing range of wellness and performance issues and goals. NIKKI provides a wide range of frequency-based solutions around sleep, energy and pain along with easing stress which can help deal with depression.

FREmedica products complement other frequency devices that monitor sleep, pain, stress and other wellness factors by actually improving the conditions they identify. Their market is our market and its growing.

ONE GOOD THING...



...AFTER ANOTHER.



For more info on financing opportunities please contact Stephen Davis at 250-732-7170 or Stephen@FrequencyExchangeCorp.com.

REVENUE OVERVIEW

Market Test:	2018	Su	Success	
WAVE 1 Soft Launch (3rd + 4th quarter):	2019	\$	1,133,524	
COVID Year: (WAVE 1)	2020	\$	833,315	
COVID Year: (WAVE 1)	2021	\$	990,000	
WAVE 1 Re-Launch after COVID:	2022	\$	879,000	

Learn more about frequencies as a timeless fact and a timely investment:

FrequencyExchangeCorp.com

COMPANY

Frequency Exchange Corp.
Common Shares Issued: 36,579,553
Trades on the Canadian Stock Exchange
Listed February 7th, 2022

TSX Venture Exchange:

FREQ.V

CONTACT

Frequency Exchange Corp. Stephen Davis, Chair & CEO 250-732-7170

Stephen@FrequencyExchangeCorp.com